Safety, Skin and Plasma Concentration of Azithromycin Dermal Formulation
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
IXODES GmbH intends to develop SHB001, an azithromycin dermal formulation in order to prevent
Lyme disease at early stages of infection after tick bite.